UK Sovereign AI fund and Stripe CEO back Potential Sciences

A new approach to chemistry

Potential Sciences, a London-based startup, is developing AI infrastructure specifically designed for scientific drug discovery. The company was founded in November of last year by Dr. Hatem Helal, who previously worked as an executive at Graphcore. The startup aims to help researchers understand how different molecules behave and interact with one another.

Unlike many current AI models that rely on large sets of previous experimental data, Potential Sciences is pioneering a different path. Their model focuses on the fundamental laws of physics to predict chemical outcomes. This shift allows the system to simulate molecular behavior based on first principles rather than just mimicking past results.

By leveraging machine learning alongside quantum chemistry simulations, the company intends to create a more accurate map of molecular interactions. This technology is intended to serve as a frontier lab for chemistry. The goal is to provide a deeper understanding of the science behind new materials and medicines.

Securing major investment

The startup recently closed a seed funding round that raised tens of millions of dollars. This round includes significant backing from the UK government’s Sovereign AI fund. The fund was established with the specific mission of ensuring the UK develops, owns, and scales key AI firms within the country.

In addition to government support, the funding includes angel investment from Stripe CEO Patrick Collison. Other participants in the round include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital, and Lightfield Equity. While the company did not disclose its exact valuation, the diversity of investors suggests high confidence in the project.

The Sovereign AI fund is also committing compute capacity to Potential Sciences. Compute capacity refers to the processing power required to run complex AI models. This support ensures the startup has the necessary hardware resources to perform its high-level quantum chemistry simulations.

The physics-first advantage

The core innovation of Potential Sciences lies in its focus on physics-based AI. Most existing models are trained on what has already happened in a lab, which can limit their ability to discover entirely new types of chemicals. By focusing on physics, the model can explore theoretical possibilities that haven't been tested yet.

The startup claims that this specific approach could make the calculations needed to design chemicals 100 times cheaper than current methods. Reducing the cost of these simulations is a major hurdle in the pharmaceutical industry. Lowering the barrier to entry for chemical design could accelerate the pace of research for new drugs.

This methodology allows for a more efficient way to navigate the vast space of possible molecular combinations. Instead of running every possible experiment, researchers can use the AI to narrow down the most promising candidates. This efficiency is what the startup hopes will fundamentally change how the field of chemistry works.

Strategic UK interests

The involvement of the Sovereign AI fund highlights a broader strategy by the UK government. The fund has made several other bets on the domestic AI landscape, including chip startup Olix and other firms like Ineffable Intelligence and Callosum. These investments are part of a push to build a sovereign AI ecosystem.

By backing Potential Sciences, the government is positioning the UK as a leader in AI-driven science. The startup's founder, Dr. Helal, is described by investment partner Joséphine Kant as a founder who combines technical excellence with ambition. She noted that he is deliberate about bringing in people who are exceptional in different areas to complement his expertise.

The partnership suggests that the UK views AI in drug discovery as a critical infrastructure. Owning the underlying technology for these simulations is a key part of the government's plan. This move aims to ensure that the benefits of these scientific advancements remain accessible and scalable within the UK's own borders.

Impact on drug discovery

The potential impact of this technology on the pharmaceutical industry is significant. Drug discovery is currently a slow and expensive process that requires massive amounts of laboratory testing. If AI can accurately predict how a drug will behave in the body using physics, it could save years of research time.

For researchers, this means a faster path from a theoretical idea to a physical compound. It allows for the exploration of complex molecules that might be too difficult or expensive to simulate using traditional methods. The startup's goal is to provide a tool that makes these complex calculations more affordable for everyone.

As the company moves forward, it will likely become a key player in how new medicines are designed. By making the process 100 times cheaper, it could democratize access to high-level chemical research. This could lead to a surge in new treatments for diseases that currently lack viable pharmaceutical options.